These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9795397)

  • 41. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
    Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan.
    Gargano LM; Hajjeh R; Cookson ST
    Vaccine; 2017 Jan; 35(3):435-442. PubMed ID: 27989625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Partridge S; Alvey J; Bernstein H; Blatter M; Bottenfield G; Guerrero J; Senders SD; Schuerman L; Cheuvart B; Holmes SJ
    Vaccine; 2007 Feb; 25(10):1806-13. PubMed ID: 17240493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria-tetanus-acellular pertussis-hib-hepatitis B combined vaccine in infants.
    Pichichero ME; Voloshen T; Zajac D; Passador S
    J Infect Dis; 1999 Oct; 180(4):1390-3. PubMed ID: 10479180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid.
    Bernstein HH; Seyferth ER
    Vaccine; 2017 Dec; 35(48 Pt B):6707-6711. PubMed ID: 29054729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.
    Sun Y; Christensen J; Hviid A; Li J; Vedsted P; Olsen J; Vestergaard M
    JAMA; 2012 Feb; 307(8):823-31. PubMed ID: 22357833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Private-sector vaccine purchase costs and insurer payments: a disincentive for using combination vaccines?
    Clark SJ; Cowan AE; Freed GL
    Hum Vaccin; 2011 Apr; 7(4):426-8. PubMed ID: 21389778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New acellular pertussis-containing paediatric combined vaccines.
    Pines E; Barrand M; Fabre P; Salomon H; Blondeau C; Wood SC; Hoffenbach A
    Vaccine; 1999 Mar; 17(13-14):1650-6. PubMed ID: 10194818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine.
    Southern J; Crowley-Luke A; Borrow R; Andrews N; Miller E
    Vaccine; 2006 Jan; 24(2):215-9. PubMed ID: 16112255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
    Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
    Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.
    Kiely M; Billard MN; Toth E; Zafack JG; Landry M; Skowronski DM; De Serres G
    Vaccine; 2018 Oct; 36(45):6688-6694. PubMed ID: 30269915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2000 Nov; 49(RR-13):1-8. PubMed ID: 11106289
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.
    Griffiths UK; Korczak VS; Ayalew D; Yigzaw A
    Vaccine; 2009 Feb; 27(9):1426-32. PubMed ID: 19146901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.
    Scheifele DW; Halperin SA; Smith B; Ochnio J; Meloff K; Duarte-Monteiro D
    Vaccine; 2006 Mar; 24(12):2057-64. PubMed ID: 16356598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.